Gilead Shares Updated Data From Remdesivir Study In Pediatric COVID-19 Patients

Gilead Sciences Inc GILD announced new data from an interim analysis of its ongoing, Phase 2/3 study of Veklury (remdesivir) in pediatric patients hospitalized with COVID-19.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!